Audentes Therapeutics, Inc. (BOLD) EPS Estimated At $-0.78

July 13, 2018 - By Darrel Chase

Analysts expect Audentes Therapeutics, Inc. (NASDAQ:BOLD) to report $-0.78 EPS on August, 9.They anticipate $0.09 EPS change or 10.34 % from last quarter’s $-0.87 EPS. After having $-0.74 EPS previously, Audentes Therapeutics, Inc.’s analysts see 5.41 % EPS growth. The stock decreased 0.39% or $0.15 during the last trading session, reaching $38.09. About 90,367 shares traded. Audentes Therapeutics, Inc. (NASDAQ:BOLD) has risen 142.34% since July 14, 2017 and is uptrending. It has outperformed by 129.77% the S&P500.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company has market cap of $1.40 billion. The firm is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It currently has negative earnings. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar.

More notable recent Audentes Therapeutics, Inc. (NASDAQ:BOLD) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” on June 26, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” published on June 21, 2018, Streetinsider.com published: “Evercore ISI Weighs in on Sector Implications Following Sarepta ‘Dramatic’ Gene Therapy Results” on June 19, 2018. More interesting news about Audentes Therapeutics, Inc. (NASDAQ:BOLD) were released by: Benzinga.com and their article: “38 Stocks Moving In Wednesday’s Mid-Day Session” published on June 20, 2018 as well as Bizjournals.com‘s news article titled: “Why this Peninsula cell therapy company joined biotech’s ‘unprecedented’ manufacturing boom” with publication date: June 18, 2018.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.